1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Abbott Laboratories

Abbott Laboratories

ABT
Abbott LaboratoriesUS flagNew York Stock Exchange
100.59
USD
+0.92
- -
175.21BMarket Cap

Total Valuation

Abbott Laboratories carries a market capitalization of 175.21B, placing it among publicly traded companies globally. Its enterprise value stands at 157.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap175.21B
Enterprise Value157.87B

Valuation Ratios

Abbott Laboratories trades at a trailing price-to-earnings ratio of 35.10.

PE Ratio35.10
PS Ratio4.64
PB RatioN/A
P/TBV RatioN/A
P/FCF Ratio17.61
P/OCF Ratio21.28

Enterprise Valuation

On an enterprise value basis, Abbott Laboratories trades at an EV/EBITDA multiple of 19.64 and an EV/FCF ratio of 16.95. The EV/Sales ratio of 4.64 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 27.93 provides insight into valuation relative to core operating earnings.

EV / Sales4.64
EV / EBITDA19.64
EV / EBIT27.93
EV / FCF16.95

Financial Position

Abbott Laboratories maintains a current ratio of 4.67, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 116.11, indicating elevated leverage, while an interest coverage ratio of 19.37 demonstrates strong ability to service its debt obligations.

Current Ratio4.67
Quick Ratio3.43
Debt / Equity116.11
Debt / EBITDAN/A
Interest Coverage19.37

Financial Efficiency

Abbott Laboratories posts a return on equity of 12.20 and a return on invested capital of 13.23.

Return on Equity (ROE)12.20
Return on Assets (ROA)10.71
Return on Invested Capital (ROIC)13.23
Return on Capital Employed (ROCE)11.00
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover4.28

Taxes

Over the trailing twelve months, Abbott Laboratories has paid 1.49B in income taxes, reflecting an effective tax rate of 24.89.

Income Tax1.49B
Effective Tax Rate24.89

Stock Price Statistics

Abbott Laboratories's stock has declined approximately -20.05881% over the past 52 weeks. The 50-day moving average sits at 90.22, while the 200-day moving average is 109.50.

Beta (5Y)N/A
52-Week Price Change-20.05881%
50-Day Moving Average90.22
200-Day Moving Average109.50
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Abbott Laboratories generated 33.99B in revenue and converted that into 4.50B in net income, yielding earnings per share of 2.57. EBITDA reached 8.04B, while operating income came in at 5.65B.

Revenue33.99B
Gross Profit19.11B
Operating Income5.65B
Pretax Income5.99B
Net Income4.50B
EBITDA8.04B
EBIT5.65B
Earnings Per Share (EPS)2.57

Cash Flow

Abbott Laboratories produced 7.42B in operating cash flow over the past twelve months. After subtracting -1.58B in capital expenditures, free cash flow totaled 5.83B - equivalent to 3.35 per share.

Operating Cash Flow7.42B
Capital Expenditures-1.58B
Free Cash Flow5.83B
FCF Per Share3.35

Margins

Abbott Laboratories operates with a gross margin of 56.20, reflecting its pricing power and cost economics. The operating margin of 16.63 and net profit margin of 13.23 provide insight into operational efficiency.

Gross Margin56.20
Operating Margin16.63
Pretax Margin17.61
Profit Margin13.23
EBITDA Margin23.65

Dividends & Yields

The company's payout ratio of 70.25 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share1.82
Dividend YieldN/A
Payout Ratio70.25
Shareholder Yield-8.97
FCF Yield5.68

Stock Splits

Abbott Laboratories's most recent stock split took place on January 2, 2013 with a 2399:5000 split ratio.

Last Split Date1/2/2013
Split Ratio2399:5000

Scores

Abbott Laboratories posts an Altman Z-Score of 17.96, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score17.96